Oruka Therapeutics’ (ORKA) “Outperform” Rating Reiterated at Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $165.00 price target on the stock. Wedbush‘s target price indicates a potential upside of 73.53% from the company’s previous close.

ORKA has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a report on Tuesday. Finally, Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock traded up $4.76 during mid-day trading on Tuesday, reaching $95.09. 666,863 shares of the stock traded hands, compared to its average volume of 1,084,757. Oruka Therapeutics has a 12-month low of $25.23 and a 12-month high of $115.51. The stock has a market capitalization of $6.30 billion, a PE ratio of -46.90 and a beta of -0.37. The business’s 50-day moving average is $89.99 and its 200-day moving average is $67.22.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities analysts anticipate that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $74.81, for a total transaction of $523,670.00. Following the completion of the sale, the insider directly owned 31,771 shares of the company’s stock, valued at approximately $2,376,788.51. This represents a 18.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $83.62, for a total value of $2,090,500.00. Following the completion of the transaction, the chief executive officer directly owned 923,128 shares in the company, valued at $77,191,963.36. The trade was a 2.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 154,950 shares of company stock worth $14,102,680 over the last quarter. 23.49% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Oruka Therapeutics in the second quarter valued at approximately $474,916,000. Jupiter Topco LLC acquired a new position in Oruka Therapeutics during the second quarter worth $130,968,000. Remedium Capital Partners LLC grew its stake in Oruka Therapeutics by 0.9% in the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after purchasing an additional 13,247 shares in the last quarter. Avidity Partners Management LP grew its stake in Oruka Therapeutics by 15.1% in the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at about $33,578,000. 56.44% of the stock is owned by institutional investors and hedge funds.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Oruka reported positive Week 16 results from the Phase 2b EVERLAST-B trial in moderate-to-severe psoriasis. In the 600 mg high-dose group, 61% of patients achieved complete skin clearance (PASI 100), while 86% achieved PASI 90. The company said the efficacy was highly similar to the earlier EVERLAST-A study, with a favorable safety and tolerability profile consistent with the IL-23p19 drug class. Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001
• Positive Sentiment: The data prompted substantial market optimism, with reports highlighting the 61% complete-clearance rate and describing ORKA-001 as potentially differentiated in psoriasis. Guggenheim reportedly estimated the treatment could generate as much as $7 billion in peak sales, increasing the perceived value of Oruka’s pipeline. Oruka’s psoriasis treatment could generate $7B in peak sales
• Positive Sentiment: Management expects ORKA-001 to enter Phase 3 trials in the first half of 2027. Additional catalysts include 52-week EVERLAST-A results expected in December 2026 and ORKA-002 Phase 2 psoriasis results expected in the first quarter of 2027. Oruka Therapeutics trial update
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and assigned a $165 price target, implying significant upside from the stock’s recent level and reinforcing the bullish analyst view. Wedbush stock recommendations
• Neutral Sentiment: Reported short interest was listed at zero shares as of October 26, producing a zero-day days-to-cover ratio. This suggests short covering is unlikely to be a major explanation for the move, although the data may reflect a reporting anomaly.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.